Cadence Capital Management LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,010 shares of the life sciences company’s stock, valued at approximately $799,000.
A number of other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Illumina by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Illumina by 3.1% during the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after acquiring an additional 76,452 shares during the last quarter. Capital World Investors lifted its position in Illumina by 23.8% during the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new stake in Illumina during the second quarter worth approximately $211,584,000. Institutional investors and hedge funds own 91.75% of the company’s stock.
Several equities research analysts have issued reports on the stock. BidaskClub downgraded shares of Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Canaccord Genuity restated a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. Goldman Sachs Group restated a “neutral” rating and set a $200.00 price objective on shares of Illumina in a research report on Tuesday, September 26th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $200.88.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the firm posted $0.97 earnings per share. equities analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
In related news, SVP Oene Mark Van sold 1,250 shares of Illumina stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total value of $259,700.00. Following the transaction, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at $2,428,922.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $211.11, for a total transaction of $4,222,200.00. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at $113,825,445.36. The disclosure for this sale can be found here. Insiders sold 159,215 shares of company stock worth $33,157,449 over the last three months. 0.89% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “4,010 Shares in Illumina, Inc. (ILMN) Acquired by Cadence Capital Management LLC” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/05/4010-shares-in-illumina-inc-ilmn-acquired-by-cadence-capital-management-llc.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.